pocketful logo
Valiant Laboratories Ltd logo

Valiant Laboratories Ltd

NSE: VALIANTLAB BSE: 543998

57.28

(-3.08%)

Mon, 02 Mar 2026, 05:02 pm

Valiant Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    309.42

  • Net Profit

    -2.20

  • P/B

    1.42

  • Sector P/E

    32.50

  • P/E

    0

  • EV/EBITDA

    0

  • Debt/Equity (Industry)

    0.23

  • Interest Cover (Industry)

    10.03

  • ROCE (Industry)

    12.82

  • RONW (Industry)

    12.23

  • ROE

    -1.43

  • ROCE

    -0.95

  • Debt/Equity

    0.42

  • EPS (TTM)

    0

  • Dividend Yield

    0

  • Book Value

    58.43

  • Interest Cover

    -17.66

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters74.9474.9474.9474.9474.94
FII0.010.020.630.640.00
DII000.4600
Public25.0525.0423.9724.4225.06
Government00000

Read More

Technical Analysis

RSI

36.10

MACD

-1.44

50 DMA

63.47

200 DMA

82.43

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic85.5973.0965.1960.5952.6948.0935.59
Fibonacci73.0968.3265.3760.5955.8252.8748.09
Camarilla60.7259.5758.4360.5956.1354.9953.84

Pivots Level: Classic

R3

+25

85.59

R2

+12.50

73.09

R1

+4.59

65.19

60.59
60.59
Pivot Point
LTP: 56.39

S1

-7.91

52.69

S2

-12.50

48.09

S3

-25

35.59

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    58.67

  • 20-EMA

    59.75

  • 30-EMA

    60.80

  • 50-EMA

    63.16

  • 100-EMA

    69.07

  • 200-EMA

    78.31

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
11 Feb 2026board-meetingsQuarterly Results
02 Sept 2025agm
15 Jul 2025rights1:4 Rights Issue of Equity Shares19 Jul 2025
19 Jun 2025rightsRight Issue of Equity Shares19 Jul 2025
18 Jun 2025rightsRights 1:4 @ Premium Rs 65/-19 Jul 2025
17 Jul 2024agm

Read More

Peer Comparison

Valiant Laboratories Ltd logo

Valiant Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Valiant Laboratories Ltd About

Valiant Laboratories engaged in manufacturing and dealing in Pharmaceuticals and speciality chemicals.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2021

Headquarters

CEO

Mulesh Manilal Savla

Employees

Contact

Website icon

Website

http://www.valiantlabs.in

Email icon

Email

complianceofficer@valiantlabs.in

Phone icon

Phone

+91 22 49712001

Location icon

Location

104 Udyog Kshetra Mulund, Goregaon Link Rd Mulund West, Mumbai, Maharashtra, 400080

Read More

Valiant Laboratories Ltd Company History

YearHistory
1982
  • Commenced manufacture of Paracetamol
2004
  • Acquired additional Plot Nos. L-28, L-28 (part), L-29 and L-13 at Tarapur Industrial Area, Palghar, Maharashtra collectively admeasuring about 3,000 sq.mtrs
2015
  • The annual revenue from operations crossed Rs.500 million
2021
  • Converted from partnership firm into a public limited company
  • The annual revenue from operations crossed Rs.1,000 million
2022
  • The annual revenue from operations crossed Rs.2,000 million
  • Formed the wholly owned subsidiary, VASPL to diversify the business activities

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
METASONI ALLOYS PVT LTDSell774266.9817 Dec 2025
METASONI ALLOYS PVT LTDBuy31199967.3317 Dec 2025
TRADE CORNERSell235200120.2913 Jun 2025
MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITEDSell275000102.7531 Jan 2025
NECTA BLOOM VCC - NECTA BLOOM ONEBuy275000102.7531 Jan 2025
MONEY LOGIX SECURITIES PVT LTDBuy550000105.7824 Jan 2025
JAINAM BROKING LIMITEDSell550000105.7724 Jan 2025
JAINAM BROKING LIMITEDBuy12300148.5407 Jun 2024
JAINAM BROKING LIMITEDSell344380142.807 Jun 2024
JALIYAN COMMODITYBuy349143142.8107 Jun 2024

Read More

Valiant Laboratories Ltd News

Valiant Labs Gets ₹12.53 Cr GST Show-Cause Notice

Valiant Laboratories receives GST demand notice of ₹12.53 crores from CGST authorities over IPO expenses, turnover mismatch, and corporate guarantee issues dated January 14, 2026.

15 Jan 2026

stocks

Valiant Laboratories Board Addresses Stock Exchange Fine for Rights Issue Committee Meeting Delay

Valiant Laboratories Limited's Board of Directors reviewed and commented on fines imposed by BSE Limited and National Stock Exchange for non-compliance with listing regulations. The company was penalized for delayed prior intimation of a Rights Issue Committee Meeting held on July 15, 2025. The Board stated the non-compliance was not deliberate and resulted from practical challenges in scheduling the committee meeting. The Rights Issue Committee was authorized to determine key terms including issue price, record date, and entitlement ratio. The committee meeting was scheduled promptly after receiving in-principle approvals from stock exchanges (NSE approval on July 11, 2025, and BSE approval on July 14, 2025). Both stock exchanges imposed fines of ₹2,11,800 each (inclusive of GST), which the company paid on August 20, 2025, within prescribed timelines. The Board considers the matter fully complied with and closed.

11 Nov 2025

corporate governance

Valiant Laboratories Reports Appropriate Utilization of Rights Issue Proceeds for Quarter Ended September 2025

Valiant Laboratories Limited submitted its monitoring agency report for the quarter ended September 30, 2025, confirming appropriate utilization of funds raised through its rights issue. India Ratings and Research Private Limited, serving as the monitoring agency, reported no deviation from the stated objects of the rights issue. The company raised funds through 1,08,62,500 rights issue equity shares at INR 75 per share with a face value of INR 10 each. The proceeds were utilized for adjustment of unsecured loans of promoter/promoter group (INR 5,800.51 lakhs), repayment of outstanding loans of existing promoters (INR 139.51 lakhs), capital expenditure (INR 1,956.48 lakhs), general corporate purposes (INR 1,674.22 lakhs), and issue-related expenses (INR 70.00 lakhs). The report was reviewed by the Audit Committee and Board of Directors. Unutilized funds totaling INR 270.00 lakhs were deployed in fixed deposits with banks.

11 Nov 2025

corporate action

Valiant Laboratories Reports Net Profit of Rs 270.37 Lakh in Q2 FY2026

Valiant Laboratories Limited announced its audited financial results for the quarter and half-year ended September 30, 2025. The company reported a standalone net profit of Rs 270.37 lakh for Q2, compared to a net loss of Rs 609.05 lakh in the same quarter last year. Revenue from operations increased to Rs 4,598.77 lakh in Q2 from Rs 2,147.90 lakh in the previous year quarter. For the half-year period, the company achieved a net profit of Rs 161.32 lakh versus a loss of Rs 1,016.07 lakh in the corresponding period last year. The consolidated results showed similar improvement with Q2 net profit of Rs 270.52 lakh compared to a loss of Rs 607.02 lakh in the previous year. The company operates in the chemicals manufacturing business and has one subsidiary, Valiant Advanced Sciences Private Limited.

11 Nov 2025

earnings

Valiant Laboratories Subsidiary Begins Production at New Gujarat Facility

Valiant Laboratories' subsidiary has commenced production at a new manufacturing facility in Gujarat. The facility focuses on producing acetic anhydride and was funded using proceeds from the company's IPO.

07 Nov 2025

stock

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800